NeuroPace Q3 2026 revenue miss and full‑year guidance cut

NeuroPace reported third‑quarter 2026 revenue of $23.1 million, well below analyst forecasts of roughly $27 million. The company cut its full‑year 2026 revenue outlook to $91‑92 million from the prior $99.5‑101.5 million range and warned that sales‑force disruptions and account‑specific issues weighed on results. CEO Joel Becker said the shortfall was driven by transient operational challenges and that the firm is taking actions to improve execution. The earnings release triggered a sharp sell‑off, with the stock falling more than 35% after hours.

KeyBanc lowered its price target to $14 from $18 and Leerink cut its target to $7, reflecting the reduced growth outlook (KeyBanc note). The guidance cut and earnings miss have driven the stock to trade well below its prior levels, increasing downside risk for investors.

  • 1Q3 2026 revenue was $23.1 million
  • 2Revenue missed analyst expectations of $27.1 million
  • 3Full‑year 2026 revenue guidance was revised to $91 million‑$92 million
  • 4Cash and cash equivalents at quarter‑end were $49.5 million, down from $51.9 million
  • 5The stock fell about 35% in after‑hours trading following the release
  • 6CEO Joel Becker attributed the miss to sales‑force restructuring and account‑specific operational issues

Sources